Mowel (Mycophenolate Mofetil)

Mycophenolate Mofetil, the active ingredient in Mowel, is an antimetabolite presented as an oral formulation for oral use. It is employed to prevent graft rejection in organ transplantation and to treat lupus nephritis by suppressing the immune response. The drug works by inhibiting inosine monophosphate dehydrogenase, a key enzyme in lymphocyte proliferation, thereby reducing the activity of T and B cells that drive rejection and renal inflammation.

GNH USA supplies Mowel as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, pharmacies and clinics worldwide.

Mowel (mycophenolate mofetil) is used in immunosuppressive therapy to manage conditions that involve unwanted immune activation.

- Organ transplantation (kidney, heart, liver, pancreas): helps prevent acute graft rejection and supports long‑term graft survival. - Lupus nephritis: reduces renal inflammation, proteinuria and disease progression. - Bone marrow transplantation (GVHD prophylaxis): lowers the risk of graft‑versus‑host disease after hematopoietic stem‑cell transplant.

Adverse reactions to Mowel vary in frequency and severity.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Diarrhea: watery stools, sometimes requiring fluid replacement. - Headache: transient, often resolves with continued therapy. - Tremor: fine shaking of hands or limbs. - Infections: increased susceptibility to bacterial, viral or fungal infections. - Leukopenia: reduced white‑blood‑cell count, may be asymptomatic.

Serious or Rare Side Effects: - Severe infection: opportunistic infections such as Pneumocystis jirovecii pneumonia. - Malignancy: heightened risk of lymphoproliferative disorders. - Bone‑marrow suppression: anemia, thrombocytopenia, pancytopenia. - Hepatic toxicity: elevated liver enzymes or hepatitis. - Progressive multifocal leukoencephalopathy (PML): rare demyelinating disease of the CNS.

Before initiating Mowel, clinicians should consider several safety measures.

- Monitor blood counts: perform regular complete blood count tests to detect leukopenia or anemia. - Assess liver function: check hepatic enzymes periodically. - Avoid live vaccines: live attenuated vaccines may cause infection while immunosuppressed. - Use effective contraception: teratogenic risk is unknown; pregnancy should be avoided. - Adjust dose in renal impairment: reduced clearance may require dose modification. - Store at below 25°C: keep in the original container, protect from moisture and direct sunlight.

Mowel can interact with other medicines, altering efficacy or safety.

Major Interactions (Avoid): - Azathioprine: additive bone‑marrow suppression. - Cyclosporine or tacrolimus: increased nephrotoxicity and infection risk. - Live vaccines: heightened risk of vaccine‑derived disease. - Cholestyramine or colestipol: may reduce mycophenolate absorption.

Moderate Interactions (Monitor Closely): - Warfarin: potential alteration of anticoagulant effect, monitor INR. - Antacids containing aluminum or magnesium: may affect drug bioavailability. - Rifampin: induces metabolism, possibly lowering mycophenolate levels. - Fluconazole: inhibits metabolism, may increase exposure. - ACE inhibitors: monitor renal function when combined with nephrotoxic agents.